http://www.rxpgnews.com/ Medical News and Information Thu, 21 Aug 2008 02:00:28 PST en-us http://www.rxpgnews.com/darbepoetinalfa/FDA_approves_extended_dosing_of_Aranesp_3805_3805.shtml Darbepoetin Alfa Amgen (NASDAQ: AMGN), the world's largest biotechnology company, today announced the U.S. Food and Drug Administration (FDA) has approved every-three-week dosing of Aranesp® (darbepoetin alfa) for the treatment of chemotherapy-induced anemia (low red blood cell count) in patients with non-myeloid malignancies. Aranesp is the only erythropoiesis-stimulating agent approved by the FDA for every-three-week administration. Tue, 28 Mar 2006 19:59:00 PST http://www.rxpgnews.com/darbepoetinalfa/FDA_approves_extended_dosing_of_Aranesp_3805_3805.shtml http://www.rxpgnews.com/darbepoetinalfa/Study_Suggests_Drug_For_Chemotherapy-Induced_Anemi_3806_3806.shtml Darbepoetin Alfa Parallel administration of chemotherapy and an anti-anemia drug called darbepoetin alfa every 3 weeks is safe and effective, according to a new study. Wed, 15 Feb 2006 20:01:00 PST http://www.rxpgnews.com/darbepoetinalfa/Study_Suggests_Drug_For_Chemotherapy-Induced_Anemi_3806_3806.shtml http://www.rxpgnews.com/darbepoetinalfa/Interim_Aranesp_data_suggest_major_response_in_ane_3807_3807.shtml Darbepoetin Alfa Amgen (NASDAQ: AMGN), the world's largest biotechnology company, today announced updated interim data from a Phase 2 study evaluating the use of 500 mcg of Aranesp darbepoetin alfa) administered every three weeks to treat anemia in patients with a bone marrow disorder known as myelodysplastic syndrome (MDS). Low-risk MDS patients receiving Aranesp every three weeks, who had no prior erythropoietic therapy, exhibited an overall response of 70 percent, increased hemoglobin levels and improvements in patient-reported fatigue. Tue, 13 Dec 2005 20:06:00 PST http://www.rxpgnews.com/darbepoetinalfa/Interim_Aranesp_data_suggest_major_response_in_ane_3807_3807.shtml http://www.rxpgnews.com/darbepoetinalfa/Interim_data_suggest_major_response_with_Aranesp_R_3810_3810.shtml Darbepoetin Alfa Amgen Inc. (NASDAQ:AMGN), the world's largest biotechnology company, today announced new interim data from a Phase 2 study evaluating the use of 500 mcg of Aranesp(R) (darbepoetin alfa) every three weeks to treat anemia in patients with a bone marrow disorder known as myelodysplastic syndromes (MDS). The data were presented at the 17th International Symposium of the Multinational Association of Supportive Care in Cancer (MASCC) in Geneva. (Abstract #02-007) Sun, 10 Jul 2005 20:17:00 PST http://www.rxpgnews.com/darbepoetinalfa/Interim_data_suggest_major_response_with_Aranesp_R_3810_3810.shtml http://www.rxpgnews.com/darbepoetinalfa/Aranesp_dosed_every_three_weeks_achieved_and_maint_3812_3812.shtml Darbepoetin Alfa Amgen Inc., (NASDAQ: AMGN) the world's largest biotechnology company, today announced that new interim data from a single-arm, open label study of 1,225 cancer patients receiving chemotherapy demonstrated that Aranesp® (darbepoetin alfa) administered every three weeks was effective in increasing and maintaining patient hemoglobin levels to the recommended target of greater than or equal to 11 g/dL. Further, treatment with Aranesp reduced the need for red blood cell transfusions in cancer patients with chemotherapy-induced anemia. Mon, 16 May 2005 20:27:00 PST http://www.rxpgnews.com/darbepoetinalfa/Aranesp_dosed_every_three_weeks_achieved_and_maint_3812_3812.shtml http://www.rxpgnews.com/darbepoetinalfa/Final_results_demonstrate_Aranesp_dosed_every_two__3811_3811.shtml Darbepoetin Alfa Amgen Inc., (NASDAQ: AMGN) the world's largest biotechnology company, today announced that final results of a Phase 3 randomized, head-to-head study demonstrated that 200 mcg of Aranesp® (darbepoetin alfa) administered every two weeks is as effective as 40,000 U of Epoetin alfa dosed once a week in boosting hemoglobin levels and reducing the need for red blood cell transfusions in cancer patients with chemotherapy-induced anemia. Mon, 16 May 2005 20:23:00 PST http://www.rxpgnews.com/darbepoetinalfa/Final_results_demonstrate_Aranesp_dosed_every_two__3811_3811.shtml http://www.rxpgnews.com/darbepoetinalfa/Anemia_drug_reduces_transfusions_and_chemotherapy-_3809_3809.shtml Darbepoetin Alfa Patients treated with darbepoetin alfa (AranespTM) for chemotherapy-induced anemia may require fewer blood transfusions and feel less fatigued than patients receiving a placebo, concludes a new study in the August 21 issue of the Journal of the National Cancer Institute. Wed, 28 Aug 2002 20:15:00 PST http://www.rxpgnews.com/darbepoetinalfa/Anemia_drug_reduces_transfusions_and_chemotherapy-_3809_3809.shtml